Patients with inflammatory bowel disease discontinued methotrexate therapy at twice the rate seen in those who used optimized thiopurine therapy, according to study results.

Abhinav Vasudevan, MPH, PhD, of the department of gastroenterology and hepatology at Eastern Health Australia, and colleagues wrote that intolerances to immunomodulators are common, and concern remains about their long-term safety despite their relatively positive efficacy.

“The choice between different immunomodulators is likely driven by clinician experience and preference, given the lack of comparative data and the

Full Article: